(Q37971324)

26 August 2017

title

Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine (English)

1 reference

26 August 2017

1 reference

1 reference

Hongmei Xu

1

1 reference

26 August 2017

Xuetao Cao

series ordinal

2

1 reference

26 August 2017

language of work or name

1 reference

1 December 2011

1 reference

26 August 2017

published in

Frontiers of medicine

1 reference

26 August 2017

volume

5

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

323-332

1 reference

26 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Cancer immunotherapy--revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Immunotherapy: bewitched, bothered, and bewildered no more

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Dendritic-cell trafficking to lymph nodes through lymphatic vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

IL-17A-producing gammadeltaT cells promote CTL responses against Listeria monocytogenes infection by enhancing dendritic cell cross-presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Clinical applications of dendritic cell vaccination in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

The use of dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Proliferating dendritic cell progenitors in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Dendritic cells under the spell of prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Cancer immunotherapy with mRNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

21 January 2018

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Migration of dendritic cell based cancer vaccines: in vivo veritas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Stress for maintaining memory: HSP70 as a mobile messenger for innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

"MIATA"-minimal information about T cell assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Development of a potency assay for human dendritic cells: IL-12p70 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Immune therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Intercellular Adhesion Molecule-1-Dependent Stable Interactions between T Cells and Dendritic Cells Determine CD8+ T Cell Memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-011-0172-4

Landmark approval for Dendreon's cancer vaccine

21 January 2018

1 reference

12 December 2020

Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine

1 reference

12 December 2020

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

12 December 2020

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity

1 reference

12 December 2020

Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration

1 reference

12 December 2020

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state

1 reference

12 December 2020

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

1 reference

12 December 2020

Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions

1 reference

12 December 2020

Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor

1 reference

12 December 2020

Immunotherapy and chemotherapy--a practical partnership

1 reference

12 December 2020

10.1007/S11684-011-0172-4

Identifiers

DOI

1 reference

26 August 2017

1 reference